Theravance Biopharma (TBPH)
(Delayed Data from NSDQ)
$9.29 USD
-0.31 (-3.23%)
Updated May 17, 2024 04:00 PM ET
After-Market: $9.30 +0.01 (0.11%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Price, Consensus and EPS Surprise
TBPH 9.29 -0.31(-3.23%)
Will TBPH be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for TBPH based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TBPH
Theravance (TBPH) Q1 Earnings Top, Revenues Match Estimates
Theravance Biopharma (TBPH) Reports Q1 Loss, Misses Revenue Estimates
TBPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Catalent (CTLT) Reports Q3 Loss, Misses Revenue Estimates
Strength Seen in Theravance Bio (TBPH): Can Its 7.6% Jump Turn into More Strength?
Nektar (NKTR) Up 7.5% Since Last Earnings Report: Can It Continue?
Other News for TBPH
Buy Rating Affirmed on Theravance Biopharma Amid Strong Q1 Performance and Promising Pipeline Prospects
Buy Rating Affirmed for Theravance Biopharma on Strong Portfolio Performance and Promising Drug Prospects
Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
Analysts Have Conflicting Sentiments on These Healthcare Companies: Theravance Biopharma (TBPH), Voyager Therapeutics (VYGR) and Praxis Precision Medicines (PRAX)
TBPH Stock Earnings: Theravance Biopharma Beats EPS, Beats Revenue for Q1 2024